Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 96

Results For "MIT"

4668 News Found

Tata Chemicals Europe to invest Rs. 655 crore on expansion of pharmaceutical grade sodium bicarbonate capacity
News | November 13, 2024

Tata Chemicals Europe to invest Rs. 655 crore on expansion of pharmaceutical grade sodium bicarbonate capacity

Construction of the plant will commence in 2025 with first production expected to be in 2027


Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr
News | November 11, 2024

Aurobindo Pharma Q2 FY25 net profit up 8.6% at Rs. 817 Cr

Growth markets revenue increased by 44 YoY to Rs. 812 crore


Zydus Wellness Q2 FY25 sales up 12% at Rs. 490.7 Cr
News | November 11, 2024

Zydus Wellness Q2 FY25 sales up 12% at Rs. 490.7 Cr

Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore


Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules
Drug Approval | November 11, 2024

Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules

Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension


Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr
News | November 11, 2024

Akums Drugs and Pharmaceuticals posts Q2 FY25 adjusted PAT at Rs. 66.7 Cr

For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore


Pfizer INDovation program boosts six start-ups with Rs. 1.5 crore grant
Startup | November 11, 2024

Pfizer INDovation program boosts six start-ups with Rs. 1.5 crore grant

The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring


USFDA classifies Biocon Biologics’ Biocon Park in Bengaluru as VAI
News | November 11, 2024

USFDA classifies Biocon Biologics’ Biocon Park in Bengaluru as VAI

The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants


Granules India’s Unit V facility secures USFDA EIR with NAI status
Drug Approval | November 10, 2024

Granules India’s Unit V facility secures USFDA EIR with NAI status

The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit


Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr
News | November 10, 2024

Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr

Q2 FY25 Total Income was at Rs. 85.4 crore